NCT03435627 - Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 26, 2018

Primary Completion Date

January 18, 2022

Study Completion Date

January 18, 2022

Conditions

Genetic DisorderNoonan Syndrome

Interventions

DRUG

Somatropin

Participants will be treated with commercially available Norditropin® (somatropin) according to routine clinical practice at the discretion of the treating physician.

Trial Locations (22)

078-8510

Novo Nordisk Investigational Site, Asahikawa, Hokkaido

830-0011

Novo Nordisk Investigational Site, Fukuoka

216-8511

Novo Nordisk Investigational Site, Kanagawa

232-8555

Novo Nordisk Investigational Site, Kanagawa

602-8566

Novo Nordisk Investigational Site, Kyoto

629-2261

Novo Nordisk Investigational Site, Kyoto

371-8511

Novo Nordisk Investigational Site, Maebashi-shi, Gunma

889-1692

Novo Nordisk Investigational Site, Miyazaki

467-8602

Novo Nordisk Investigational Site, Nagoya, Aichi

951 8520

Novo Nordisk Investigational Site, Niigata-shi, Niigata

534-0021

Novo Nordisk Investigational Site, Osaka

594-1101

Novo Nordisk Investigational Site, Osaka

879-5593

Novo Nordisk Investigational Site, Ōita

330-8777

Novo Nordisk Investigational Site, Saitama-shi, Saitama

065-8611

Novo Nordisk Investigational Site, Sapporo, Hokkaido

980 8574

Novo Nordisk Investigational Site, Sendai-shi, Miyagi

431-3192

Novo Nordisk Investigational Site, Shizuoka

329-0498

Novo Nordisk Investigational Site, Tochigi

157 8535

Novo Nordisk Investigational Site, Tokyo

160-8582

Novo Nordisk Investigational Site, Tokyo

162-8666

Novo Nordisk Investigational Site, Tokyo

183-8561

Novo Nordisk Investigational Site, Tokyo